Generic name: SELEXIPAG 200ug
Dosage form: tablet, coated
Medically reviewed by Drugs.com. Last updated on Sep 10, 2019.
The recommended starting dose of UPTRAVI is 200 micrograms (mcg) given twice daily. Tolerability may be improved when taken with food [see Clinical Pharmacology (12.3)].
Increase the dose in increments of 200 mcg twice daily, usually at weekly intervals, to the highest tolerated dose up to 1600 mcg twice daily. If a patient reaches a dose that cannot be tolerated, the dose should be reduced to the previous tolerated dose.
Do not split, crush, or chew tablets.
Interruptions and Discontinuations
If a dose of medication is missed, patients should take a missed dose as soon as possible unless the next dose is within the next 6 hours.
If treatment is missed for 3 days or more, restart UPTRAVI at a lower dose and then retitrate.
Dosage Adjustment in Patients with Hepatic Impairment
No dose adjustment of UPTRAVI is necessary for patients with mild hepatic impairment (Child-Pugh class A).
For patients with moderate hepatic impairment (Child-Pugh class B), the starting dose of UPTRAVI is 200 mcg once daily. Increase in increments of 200 mcg once daily at weekly intervals, as tolerated [see Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].
Avoid use of UPTRAVI in patients with severe hepatic impairment (Child-Pugh class C).
Dosage Adjustment with Co-administration of Moderate CYP2C8 Inhibitors
When co-administered with moderate CYP2C8 inhibitors (e.g., clopidogrel, deferasirox and teriflunomide), reduce the dosing of UPTRAVI to once daily. Revert back to twice daily dosing frequency of UPTRAVI when co-administration of moderate CYP2C8 inhibitor is stopped [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Uptravi (selexipag)
- Side Effects
- During Pregnancy
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 18 Reviews
- Drug class: agents for pulmonary hypertension
- FDA Approval History